Interesting!

Journal Article Corrected proof Editor's Choice Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial Open Access Michelle K Yong , Karin Thursky , Megan Crane , Tim Spelman , Robert K Mahar , Julie A Simpson , Andrew M Scott , Simon J Harrison , Jeff Szer , Marc Pellegrini ... Show more Author Notes Clinical Infectious Diseases, ciaf409, https://doi.org/10.1093/cid/ciaf409 Published: 28 August 2025 Article history

Study: Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial.

Published: 28 August 2025

Source: academic.oup.com/cid/advance-...

Australian-led trial shows nasal spray reduces COVID-19 risk in cancer patients - Peter MacCallum Cancer Centre

Australian-led trial shows nasal spray reduces COVID-19 risk in cancer patients.

"The research... showed that a nasal spray containing interferon-alpha (IFN-α), a naturally occurring protein with broad antiviral activity, could reduce the risk of COVID-19 infection by 40% compared to placebo."

Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial In this randomized, double-blind, placebo-controlled trial, 433 participants received daily nasal spray 40 000 IU IFN-α or placebo for 3 months. The primar

With COVIDhge, we previously ✍🏼 about IFN therapy for COVID, based on findings that 🧬mutations or auto-Abs to type I IFN caused severe COVID.
Now, an RCT shows this concept extends more broadly👇🏼

Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients academic.oup.com/cid/article/...

Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial In this randomized, double-blind, placebo-controlled trial, 433 participants received daily nasal spray 40 000 IU IFN-α or placebo for 3 months. The primar

In this RCT, 433 adults w/cancer randomized to daily IFN-alpha or placebo nasal spray. Incidence of COVID was significantly different at 8.3% w/ IFN-alpha vs 14.4% in control, w/ no difference in other resp viruses (similar in vaccinated subgroup)… #IDSky

academic.oup.com/cid/advance-...

🔥🔥Just published in #CID world-first clinical trial of IFN-a nasal spray vs placebo reduced #COVID 🦠 incidence 📉 by 40% in cancer pts. Well tolerated, safe, effective…

Full link here: academic.oup.com/cid/advance-ar…

Day 2 of the @petermaccc.bsky.social Research Symposium opened with A/Prof @michyong.bsky.social plenary on "Transforming the care of Infectious Diseases in Cancer Patients." Discussing groundbreaking research and future directions in fungal, viral, bacterial, and vaccine clinical trials.

Grateful to have received a travel stipend to spend an exciting few days at the @fredhutch.bsky.social ICH Symposium in Seattle, present & learn from experts in the field- Including @kottonnelson.bsky.social, Jay Fishman & our own @ncicancer.bsky.social @michyong.bsky.social, Monica Slavin & more..!

Prof Monica Slavin at the meet the experts on Mycology clinical trials- have you participated?#escmidglobal

We are excited for #ESCMIDGLOBAL - the premier event for Infectious Diseases and Microbiology hosted by @escmid.bsky.social in Vienna, Austria! 🌍
If you're planning to attend, we’d love to connect with you. Below are the details of our presentations, including titles, times, and locations.

Honoured to speak & present our @ncicancer.bsky.social work on infection prevention in cancer/transplant at the Australasian Society of ID ASM with @nikhil-singh.bsky.social @michyong.bsky.social @benwteh.bsky.social, & amazing to hear & see the incredible work done at other centres nationally 👏🏽

Join A/Professor @michyong.bsky.social this Thursday 3rd of April at 10 am ET, for the @ichs-global.bsky.social Early Career virtual networking session to connect, collaborate, and shape the future of Early Career programs!

To learn more and sign up: ichs.wildapricot.org/page-1863364

Great 1st day at Australasian Society for Infectious Diseases meeting!

@michyong.bsky.social led an insightful CMV symposium

@benwteh.bsky.social chaired the "What's New in.." session as part of ICHSIG

@priyagargiddoc.bsky.social comprehensive talk on key developments and gaps in the ICHS space

Trusted research on Europe PMC: Access a free collection of biomedical research: 45M articles and preprints with 10M as full text.

Research links on Europe PMC: Explore connected research with links to open data, peer reviews, protocols and more.

Developer tools on Europe PMC: Innovate with resources for developers, from open APIs to training datasets and ML models.

Europe PMC is a trusted platform: Supported by 35 funders, developed by EMBL-EBI and partner with PubMed Central.

Hello, Bluesky!👋 We are excited to connect with you!🌟
Europe PMC is an open database of global life science research - discover articles, preprints, theses, grants, and more. We talk about scholarly communication, open science, bioinformatics, and meta research. Follow us and join the conversation!

Kicking off the #pharmacysymposium
We have @michyong.bsky.social highlighting the use of marabivir in tricky #ID populations #CMV and real world use beyond the clinical trials. (With promising clinical effectiveness) #antiviralstewardship
#antimicrobials2025

Immune Monitoring Assays: Predicting Cytomegalovirus and... : Transplantation An abstract is unavailable.

If it's written by @kottonnelson.bsky.social, it is a must read!

Concise expert insight into the utility of Immune monitoring assays for Cytomegalovirus.

journals.lww.com/transplantjo...

Thanks @sonkoning.bsky.social . We’ve learnt so much over the years… more promising therapies to come

What a great meeting! @ausantibiotics.bsky.social

#ASA2025 in Melbourne! 🌟
@michyong.bsky.social discussed alternative antiviral treatments for COVID-19. Last night, Prof Karin Thursky delivered the prestigious Howard Florey Oration, and today, A/Prof Gabrielle Haesuler led the 'Year in Review' session. Inspiring moments from our leaders!

Happy International Women in Science Day!

With over 85% of our cohort being women, we are dedicated to promoting, supporting, and strengthening women in science!

Discover the achievements of these women here:
cancerandinfections.org/phd-pathways

@michyong.bsky.social @abbydouglas.bsky.social

Really interesting paper by my colleagues at @domucla.bsky.social - and fits with my own thoughts about the utility/pitfalls of plasma mcfDNA (including low yield of fungal pickup) as well as giving some ideas for future diagnostic stewardship if incorporated into practice @jschaenmanmd.bsky.social

Congratulations Tori!

New virtual meeting for Immunocompromised Host Society: Addressing the Landscape of CMV Management in Transplant Recipients. Free to members or $25 plus a free membership for those not already members!

Forward on to your residents, fellows, grad students, and international colleagues

#TxID #CMV

Thanks @germhuntermd.bsky.social ! Wow the ICH #TxID group is growing by the day. Just updated and followed - thanks for making it easier to find our friends and colleagues.

Australian adoption paperwork is underway @kottonnelson.bsky.social !Love these photos!

Thanks, @michyong.bsky.social it was wonderful to spend time at Peter Mac! An amazing place with world-class care. Case discussions were great! Such an honor to be there with you all.

Forbes Oration about to start.
Camille Kotton is our Forbes Fellow this year.

‘Let us help you: Better living through transplant infectious diseases’

@kottonnelson.bsky.social
#IDSky

Hello bsky community!! We welcomed Camille Kotton to Melbourne as our 2024 Forbes Fellow. She shared her wisdom, knowledge on all things ID. What a star! @kottonnelson.bsky.social @bradgardiner.bsky.social #TxID